8-K: RxSight Reports Strong Q4 and Full-Year 2024 Results, Reaffirms 2025 Guidance

RxSight, Inc. announces a 41% increase in fourth-quarter revenue and a 57% increase in full-year revenue for 2024, driven by strong sales of Light Adjustable Lenses and Light Delivery Devices.

Summary

• RxSight, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Fourth-quarter revenue reached $40.2 million, a 41% increase compared to the same period in 2023.
• This growth was fueled by a 61% increase in Light Adjustable Lens (LAL/LAL+) procedure volume, with 29,069 units sold.
• The company also sold 83 Light Delivery Devices (LDDs), expanding the installed base to 971 units, a 46% increase year-over-year.
• Full-year 2024 revenue totaled $139.9 million, a 57% increase compared to 2023.
• This was driven by sales of 98,055 LALs and 305 LDDs, representing growth of 79% and 15%, respectively.
• The company reported a net loss of $(5.9) million for the fourth quarter, or $(0.15) per share, compared to a net loss of $(9.2) million, or $(0.26) per share, in the fourth quarter of 2023.
• Adjusted net earnings for the fourth quarter were $1.3 million, or $0.03 per share, compared to an adjusted net loss of $(4.8) million, or $(0.13) per share, in the fourth quarter of 2023.
• For the full year, the net loss was $(27.5) million, or $(0.71) per share, compared to a net loss of $(48.6) million, or $(1.41) per share, in 2023.
• Adjusted net loss for the full year was $(2.8) million, or $(0.07) per share, compared to an adjusted net loss of $(31.1) million, or $(0.90) per share, in 2023.
• RxSight reaffirmed its full-year 2025 revenue guidance of $185.0 million to $197.0 million, representing growth of approximately 32% to 41% compared to 2024.
• The company also expects a gross margin in the range of 71% to 73% and operating expenses in the range of $165.0 million to $170.0 million for 2025.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, improved gross margins, and reaffirmed guidance. While the company is still reporting net losses, the trend is improving, and management expresses confidence in future growth.

Positives

• Significant revenue growth in both Q4 and full-year 2024, driven by strong LAL and LDD sales.
• Improved gross profit margin for both Q4 and full-year 2024.
• Reduction in net loss and adjusted net loss compared to the previous year.
• Strong cash position with $237.2 million in cash, cash equivalents, and short-term investments as of December 31, 2024.
• Reaffirmation of positive revenue and gross margin guidance for 2025.

Negatives

• The company reported a net loss for both the fourth quarter and the full year of 2024, although the losses were reduced compared to the previous year.
• Total operating expenses increased for both the fourth quarter and the full year of 2024, driven by investments in sales and marketing and costs of operating as a public company.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• These risks are detailed in the company's filings with the Securities and Exchange Commission (SEC), including the Annual Report on Form 10-K for the year ended December 31, 2024.

Future Outlook

RxSight is reiterating its full-year 2025 revenue guidance of $185.0 million to $197.0 million, with a gross margin in the range of 71% to 73% and operating expenses in the range of $165.0 million to $170.0 million.

Management Comments

• Dr. Ron Kurtz, Chief Executive Officer and President of RxSight, stated that adjustability has the potential to transform the premium cataract market and that the company is still in the early stages of realizing this vision.
• Management is excited by the opportunity to further expand adoption globally, advance the company's technology, and continue delivering exceptional outcomes for both patients and practices.

Industry Context

RxSight operates in the ophthalmic medical device industry, specifically focusing on customized vision solutions following cataract surgery. The company's Light Adjustable Lens system is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, giving them a competitive advantage in the premium cataract market.

Comparison to Industry Standards

• Alcon, Johnson & Johnson Vision, and Bausch + Lomb are major players in the broader IOL market.
• RxSight differentiates itself through its unique post-operative adjustability feature, targeting the premium segment of the market.
• The 57% revenue growth significantly outpaces the overall growth rate of the global ophthalmic devices market, suggesting RxSight is gaining market share.
• Companies like STAAR Surgical also operate in the refractive surgery space, but RxSight's focus on post-cataract adjustability provides a distinct value proposition.

Stakeholder Impact

• Shareholders can expect continued growth and potential for increased profitability.
• Employees may benefit from increased job security and potential for career advancement.
• Customers (patients) can expect continued access to innovative vision correction technology.
• Suppliers may benefit from increased demand for RxSight's products.

Next Steps

• The company will host a conference call on February 25, 2025, to discuss its fourth-quarter 2024 financial results.
• RxSight plans to continue expanding adoption globally, advancing its technology, and delivering exceptional outcomes for patients and practices.

Key Dates